TRINTELLIX® (vortioxetine) is indicated for the treatment of Major Depressive Disorder (MDD) in adults.

Savings & Support

Concerned about cost and access? We're here for you and your patients

~85% of commercial lives without PA

TRINTELLIX is available for ~85% of commercially insured patients in the United States without prior authorization (PA)*

*Formulary data are provided by Fingertip Formulary® and are current as of September 2022. Check patient’s individual health plan for coverage and cost information, which may change without notice.


There are 2 ways for eligible patients to enroll in the TRINTELLIX Savings Program

The TRINTELLIX Savings Card may help patients pay less for their prescriptions

  • 77% of commercial patients pay $10 or less per 30- or 90-day prescription

Only commercially insured patients ages 18 and older with a valid prescription are eligible for the TRINTELLIX Savings Card. Savings up to $100 per 30-day or $300 per 90-day prescription. See Savings Card for full Eligibility Requirements and Terms & Conditions.

Another way for patients to enroll is:

Text ‘TSAVE2’ to 36395 to access your Savings Card directly on your phone.

Message & data rates may apply. Average of 10 texts per month, but frequency varies. Text ‘HELP’ to 36395
for info, text ‘STOP’ to 36395 to end. See full terms & conditions.

Request Samples

Is your office running low on TRINTELLIX samples? Just visit MySampleCloset and
follow the steps below.

  • Login or register to create a new account (upon login, you may be prompted to complete a few security questions)
  • View the list of products and select TRINTELLIX
  • Place and submit your order. Maximum order quantities are listed on the site, one order may be placed per month.

Please note that when a TRINTELLIX sample order is placed on the MySampleCloset website, your local Takeda representative will be notified so that they can expedite delivery by bringing them to your office personally. If the representative is unable to deliver your order, the samples will be shipped to your office.

Prior Authorization Assistance

For patients who require PA, PARx Solutions may be able to help. The user-friendly portal helps initiate and manage PAs while also helping ensure the accuracy of administrative components of the PA submission.

Submit a PA today at www.PARxSolutions.com

Quote: "Feeling like I have support goes a long way."

TRINTELLIX offers support for patients with MDD

When enrolled, patients can customize their experience through support tools like:

tAccess Support Program

Mobile wallet

Must meet eligibility requirements.

Informative emails

Inspiring texts and refill reminders

Chats with a tAccess advisor

1-844-654-TRIN - 8:00 am - 8:00 pm ET M-F (1-844-654-8746)

We are committed to partnering with you to help provide support for MDD patients:

  • Education around the symptoms of Major Depressive Disorder
  • Encouragement of dialogue with you, their healthcare professional
  • Tips and tools that reinforce the conversations you have with your patients


SMS and Notifications Terms & Conditions

  • By opting in to text messages and push notifications from the Savings Program or tAccess Support Program (both the “Program”), you consent to receiving approximately 10 text messages and/or push notifications per month from Takeda and/or EngagedMedia using autodialer technology. Consent is not a condition of purchase. Such messages may be marketing or non-marketing messages and may include, for example, patient education information, surveys, and prescription savings opportunities. Carriers are NOT liable for delayed or undelivered messages.
  • Data obtained from you in connection with the Program(s) may include your telephone number; your carrier’s name; the date, time, and content of your text messages; and device information. This data may be used to administer the Program(s). Please read Takeda’s Privacy Notice, which is incorporated by reference into these Terms and Conditions.

 

tAccess Support Program

  • To stop receiving text messages from the tAccess Support Program, text STOP to 26785 or the short code from which you received a message. DOING SO WILL ONLY OPT YOU OUT OF TEXT MESSAGES FROM THE PROGRAM; you will remain opted in to any other Takeda text message program(s) to which you separately opted in.
  • To request more information or to obtain help, text HELP to 26785 or the short code from which you received a Program text message. You can also call customer service at 1-877-TAKEDA-7

 

Savings Program

  • To stop receiving text messages from the Savings Program, text STOP to 36395 or the short code from which you received a message. DOING SO WILL ONLY OPT YOU OUT OF TEXT MESSAGES FROM THE PROGRAM; you will remain opted in to any other Takeda text message program(s) to which you separately opted in. If receiving Program push notifications, you may unsubscribe at any time by going into the digital wallet on your device and disabling push notifications in the digital wallet Program pass or by removing the digital wallet Program pass from your device.
  • To request more information or to obtain help, text HELP to 36395 or the short code from which you received a Program text message. You can also call customer service at 1-866-279-0287.
  • In addition to the data use practices described in the Privacy Notice, Takeda may send you Program-related push notifications. Your device’s location will not be known or tracked by Takeda or its service providers or co-promotion partners. Nonetheless, you may opt out of geofencing and receiving these notifications at any time by (1) disabling location services for your digital wallet app in your device’s settings, (2) disabling notifications (i.e., automatic updates) within the digital wallet app, or (3) removing the Trintellix Savings Card from your digital wallet by selecting “Remove Pass” within the digital wallet app.
  • NO CLASS ACTIONS: you may only bring individual claims. Under no circumstance are you allowed to bring a claim as a punitive or named plaintiff or a class member in a class. Class action lawsuits, class-wide arbitrations, private attorney-general actions, and any other proceedings where someone acts in a representative capacity are not allowed. Any combining of individual proceedings must have the consent of all parties.

 

tAccess Support Program and Savings Program

  • By opting in to text messages from the Program(s), you agree to sharing your phone number with Takeda and/or EngagedMedia for the purpose of enrolling you into Program text messages.
  • You represent that you are the account holder for the mobile telephone number(s) that you provide to opt in to text messages from the Program(s). You are responsible for notifying Takeda immediately if you change your mobile telephone number. You may notify Takeda of a number change by re-opting into Program text messages.
  • Message and data rates may apply to each text message sent or received in connection with the Program(s), as provided in your mobile telephone service rate plan, in addition to any applicable roaming charges. Charges are both billed and payable to your mobile service provider or deducted from your prepaid account. Takeda does not impose a separate fee for sending text messages.
  • Neither Takeda nor EngagedMedia will be liable for any delays in the receipt of any SMS messages, as delivery is subject to effective transmission from your network operator.
  • This service is available only on US participating mobile carriers.
  • You agree to indemnify Takeda and EngagedMedia in full for all claims, expenses, and damages related to or caused in whole or in part by your failure to notify us if you change your telephone number, including but not limited to all claims, expenses, and damages related to or arising under the Telephone Consumer Protection Act.
  • Takeda may suspend or terminate your receipt of text messages if it believes you are in breach of these Terms and Conditions. Your receipt of text messages is also subject to termination in the event that your mobile telephone service terminates or lapses. Takeda reserves the right to modify or discontinue, temporarily or permanently, all or any part of the text messaging services you receive, with or without notice.
  • Takeda may revise, modify, or amend these Terms and Conditions at any time. Any such revision, modification, or amendment shall take effect when it is posted to the Trintellix website. You agree to review these Terms and Conditions periodically to ensure that you are aware of any changes. Your continued consent to receive text messages will indicate your acceptance of those changes.
  • Takeda may be required to contact you if you report an adverse event or product quality complaint.
  • Takeda reserves the right to rescind, revoke, or amend the Program(s) without notice at any time.
  • While Takeda makes reasonable efforts to include accurate, up-to-date information in the Program(s), Takeda makes no representations or warranties as to its accuracy. Takeda assumes no liability for any errors or omissions in the information communicated through the Program(s), and such information is not intended to make a diagnosis or to take the place of talking to a US healthcare professional.

Leaving TRINTELLIXHCP.COM

By clicking “Continue,” you will be leaving a Takeda and Lundbeck controlled website for a third-party website.

Please note that neither Takeda nor Lundbeck is responsible or liable for any third-party website, and the website may not be appropriate for all audiences.

  1. Trintellix (vortioxetine) prescribing information. Takeda Pharmaceuticals.
  2. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. Int J Neuropsychopharmacol. 2012;15(5):589‑600.
  3. Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME. J Clin Psychiatry. 2012;73(7):953‑959.
  4. Boulenger J-P, Loft H, Olsen CK. Int Clin Psychopharmacol. 2014;29(3):138‑149.
  5. Mahableshwarkar AR, Jacobsen P, Chen Y, Serenko M, Trivedi MH. Psychopharmacology (Berl). 2015;232(12):2061‑2070.
  6. Jacobsen P, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH. J Clin Psychiatry. 2015;76(5):575‑582.
  7. Katona C, Hansen T, Olsen CK. Int Clin Psychopharmacol. 2012;27(4):215‑223.
  8. Costa SL, Genova HM, DeLuca J, Chiaravalloti ND. Mult Scler. 2017;23(6):772‑789.
  9. McIntyre RS, Lophaven S, Olsen CK. Int J Neuropsychopharmacol. 2014;17(10):1557‑1567.
  10. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RSE. Neuropsychopharmacology. 2015;40(8):2025‑2037.
  11. Data on file. Takeda Pharmaceuticals.
  12. Data on file. Lundbeck.
  13. FDA updates Trintellix® (vortioxetine) label to include data showing improvement in processing speed, an important aspect of cognitive function in acute Major Depressive Disorder (MDD). News release. GlobeNewswire. May 2, 2018.
  14. Boulenger J-P, Loft H, Florea I. J Psychopharmacol. 2012;26(11):1408‑1416.
  15. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. J Sex Med. 2015;12(10):2036‑2048.
  16. Kambeitz JP, Howes OD. J Affect Disord. 2015;186:358-366.
  17. American Psychiatric Association. Depressive disorders. In: Diagnostic and Statistical Manual of Mental Disorders. 5th edition (DSM-5®). Arlington, VA: American Psychiatric Association; 2013:155‑188.